Business Context and Reporting Period
This Form 8-K filing by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) reports a corporate governance event dated June 20, 2025. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol QLGN.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial performance data.
Material Changes
The primary material change is the appointment of Robert B. Lim as Chair of the Audit Committee, effective immediately. He replaces Graydon Bensler, who will remain a member of the Board and the Audit Committee. The Board confirmed Mr. Lim qualifies as an independent director and an "audit committee financial expert."
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. It states there are no arrangements or understandings regarding Mr. Lim's selection and no material interests in transactions requiring disclosure under Item 404(a).
Investor Verification Checklist
- Verify the correct registrant name is Qualigen Therapeutics, Inc. (QLGN), not Aixcrypto Holdings, Inc.
- Confirm Robert B. Lim's background as a corporate commercial lawyer and former board member of Aerwins Technologies Inc.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains none.
- Check for any subsequent filings regarding the interim CEO, Kevin Richardson II, who signed this report.